In Non-Small Cell Lung cancer (NSCLC), Crizotinib showed great anti-tumor potential against EML4-ALK fusion positive carcinomas, and it has quickly gained momentum for treating a subset of NSCLC patients (16), after successful evaluation in a transgenic mouse model for lung adenocarcinoma (17). Here, EML4 is linked to non-small cell lung carcinoma.